Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Feb;67(2):379–382. doi: 10.1038/bjc.1993.69

Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.

P A Philip 1, J Carmichael 1, K Tonkin 1, P K Buamah 1, J Britton 1, M Dowsett 1, A L Harris 1
PMCID: PMC1968191  PMID: 8431370

Abstract

Eighteen consecutive patients with measurable locally advanced or metastatic pancreatic adenocarcinoma were treated with goserelin (Zoladex) 3.6 mg subcutaneously every 4 weeks. Hydrocortisone 20 milligrams twice daily was commenced with the second injection of goserelin. Objective tumour response was monitored by computerised tomography of the abdomen. There was no objective remission in disease sites. Serial measurements of serum tumour markers showed no reduction in serum CA 19-9 and CA 195 concentrations. The median duration of survival of all cases was 5 months. Administration of goserelin resulted in significant reductions in oestradiol, testosterone, androstenedione in males and reductions in FSH and LH in both males and females. The addition of hydrocortisone resulted in further reductions of androstenedione and testosterone levels in males. Thus goserelin showed no anti-tumour effect, but concentrations required for direct inhibitory effects may be higher than those required to produce effects on hormone suppression.

Full text

PDF
379

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrén-Sandberg A. Androgen influence on exocrine pancreatic cancer. Int J Pancreatol. 1989 May;4(4):363–369. doi: 10.1007/BF02938472. [DOI] [PubMed] [Google Scholar]
  2. Corbishley T. P., Iqbal M. J., Wilkinson M. L., Williams R. Androgen receptor in human normal and malignant pancreatic tissue and cell lines. Cancer. 1986 May 15;57(10):1992–1995. doi: 10.1002/1097-0142(19860515)57:10<1992::aid-cncr2820571019>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  3. Dowsett M., Goss P. E., Powles T. J., Hutchinson G., Brodie A. M., Jeffcoate S. L., Coombes R. C. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 1987 Apr 1;47(7):1957–1961. [PubMed] [Google Scholar]
  4. Dowsett M., Harris A. L., Smith I. E., Jeffcoate S. L. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. J Clin Endocrinol Metab. 1984 Jan;58(1):99–104. doi: 10.1210/jcem-58-1-99. [DOI] [PubMed] [Google Scholar]
  5. Fekete M., Zalatnai A., Comaru-Schally A. M., Schally A. V. Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas. 1989;4(5):521–528. doi: 10.1097/00006676-198910000-00001. [DOI] [PubMed] [Google Scholar]
  6. Ferguson K. M., Hayes M., Jeffcoate S. L. A standardised multicentre procedure for plasma gonadotrophin radioimmunoassay. Ann Clin Biochem. 1982 Sep;19(Pt 5):358–361. doi: 10.1177/000456328201900507. [DOI] [PubMed] [Google Scholar]
  7. Furr B. J., Woodburn J. R. Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses. J Endocrinol Invest. 1988 Jul-Aug;11(7):535–557. doi: 10.1007/BF03350179. [DOI] [PubMed] [Google Scholar]
  8. González-Barcena D., Ibarra-Olmos M. A., García-Carrasco F., Gutiérrez-Samperio C., Comaru-Schally A. M., Schally A. V. Influence of D-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomed Pharmacother. 1989;43(4):313–317. doi: 10.1016/0753-3322(89)90014-0. [DOI] [PubMed] [Google Scholar]
  9. Greenway B., Iqbal M. J., Johnson P. J., Williams R. Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J (Clin Res Ed) 1981 Sep 19;283(6294):751–753. doi: 10.1136/bmj.283.6294.751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Harris A. L., Dowsett M., Jeffcoate S. L., McKinna J. A., Morgan M., Smith I. E. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab. 1982 Oct;55(4):718–722. doi: 10.1210/jcem-55-4-718. [DOI] [PubMed] [Google Scholar]
  11. Harris A. L., Dowsett M., Smith I. E., Jeffcoate S. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. Eur J Cancer Clin Oncol. 1984 Apr;20(4):463–469. doi: 10.1016/0277-5379(84)90230-x. [DOI] [PubMed] [Google Scholar]
  12. Iqbal M. J., Greenway B., Wilkinson M. L., Johnson P. J., Williams R. Sex-steroid enzymes, aromatase and 5 alpha-reductase in the pancreas: a comparison of normal adult, foetal and malignant tissue. Clin Sci (Lond) 1983 Jul;65(1):71–75. doi: 10.1042/cs0650071. [DOI] [PubMed] [Google Scholar]
  13. Keating J. J., Johnson P. J., Cochrane A. M., Gazzard B. G., Krasner N., Smith P. M., Trewby P. N., Wheeler P., Wilkinson S. P., Williams R. A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer. 1989 Nov;60(5):789–792. doi: 10.1038/bjc.1989.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Redding T. W., Schally A. V. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci U S A. 1984 Jan;81(1):248–252. doi: 10.1073/pnas.81.1.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ritts R. E., Jr, Del Villano B. C., Go V. L., Herberman R. B., Klug T. L., Zurawski V. R., Jr Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank. Int J Cancer. 1984 Mar 15;33(3):339–345. doi: 10.1002/ijc.2910330310. [DOI] [PubMed] [Google Scholar]
  16. Robles-Diaz G., Diaz-Sanchez V., Mendez J. P., Altamirano A., Wolpert E. Low serum testosterone/dihydrotestosterone ratio in patients with pancreatic carcinoma. Pancreas. 1987;2(6):684–687. doi: 10.1097/00006676-198711000-00010. [DOI] [PubMed] [Google Scholar]
  17. Safi F., Roscher R., Beger H. G. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9. Hepatogastroenterology. 1989 Dec;36(6):419–423. [PubMed] [Google Scholar]
  18. Szende B., Srkalovic G., Groot K., Lapis K., Schally A. V. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists. Cancer Res. 1990 Jun 15;50(12):3716–3721. [PubMed] [Google Scholar]
  19. Szende B., Srkalovic G., Schally A. V., Lapis K., Groot K. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression. Cancer. 1990 May 15;65(10):2279–2290. doi: 10.1002/1097-0142(19900515)65:10<2279::aid-cncr2820651020>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  20. Szende B., Srkalovic G., Timar J., Mulchahey J. J., Neill J. D., Lapis K., Csikos A., Szepeshazi K., Schally A. V. Localization of receptors for luteinizing hormone-releasing hormone in pancreatic and mammary cancer cells. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4153–4156. doi: 10.1073/pnas.88.10.4153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Zimmerman S. E., Smith F. P., Schein P. S. Chemotherapy of pancreatic carcinoma. Cancer. 1981 Mar 15;47(6 Suppl):1724–1728. doi: 10.1002/1097-0142(19810315)47:6+<1724::aid-cncr2820471444>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES